GlassScriptPhysician profile
Jared L Connor
NPI 1992122303
$3,403.68
in general payments reported to CMS, 2019-2025
25 companies · $45.54 in 2025
The $45.54 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,406 · 2022: $861 · 2023: $683 · 2024: $408 · 2025: $45.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $842.55 | 2021-2022 | |
| Abbvie INC. | $789.71 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $427.28 | 2021-2024 | Farxiga, Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $151.12 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $150.50 | 2022-2023 | Spravato |
| Xeris Pharmaceuticals, INC. | $145.15 | 2021-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $137.94 | 2021-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $112.40 | 2021 | |
| Glaxosmithkline, LLC. | $106.42 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.31 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $77.07 | 2021 | |
| Abbott Laboratories | $53.84 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $40.36 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.97 | 2022 | |
| Corium, LLC | $37.38 | 2023-2024 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $36.76 | 2021-2023 | |
| Inspire Medical Systems, INC. | $31.28 | 2025 | Inspire |
| Amarin Pharma, INC. | $20.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.99 | 2021 | |
| Amgen INC. | $16.78 | 2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $16.34 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.97 | 2021 | |
| Acadia Pharmaceuticals INC | $14.26 | 2025 | Daybue |
| Horizon Therapeutics Plc | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.